MAP — Microba Life Sciences Income Statement
0.000.00%
Last trade - 00:00- AU$38.63m
- AU$30.98m
- AU$15.67m
- 28
- 55
- 13
- 22
Annual income statement for Microba Life Sciences, fiscal year end - June 30th, AUD millions except per share, conversion factor applied.
2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | 2025 June 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 3.73 | 4.69 | 5.42 | 12.1 | 15.7 |
| Cost of Revenue | |||||
| Gross Profit | 2.06 | 2.37 | 2.68 | 5.91 | 7.44 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 11.3 | 16.1 | 18.4 | 32.1 | 33.3 |
| Operating Profit | -7.52 | -11.5 | -13 | -20 | -17.6 |
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -7.52 | -11.5 | -12.7 | -20 | -15 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -7.52 | -11.5 | -12.7 | -19.9 | -14.9 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -7.52 | -11.5 | -12.7 | -19.9 | -14.9 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -7.52 | -11.5 | -12.7 | -19.9 | -14.9 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.033 | -0.06 | -0.038 | -0.049 | -0.033 |
| Dividends per Share |